Claims for Patent: 8,293,479

Summary for Patent: 8,293,479

Title:	Use of parathyroid hormone-related protein(PTHRP) in the diagnosis and treatment of chronic lung disease and other pathologies
Abstract:	This invention pertains to the discovery that Parathyroid Hormone-related Protein (PTHrP) can be detect and/or stage, and/or treat chronic lung diseases. In particular, it was discovered that PTHrP levels in broncho-alveolar lavage are indicative of lung \"health\" and \"disease\", and can be used to predict lung disease in patients at risk of chronic lung disease and/or to evaluate the efficacy of a ventilation regime.
Inventor(s):	Torday; John S. (Redondo Beach, CA), Rehan; Virender K. (Torrance, CA), Mink; Richard (Torrance, CA)
Assignee:	Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center (Torrance, CA)
Application Number:	10/513,474
Patent Claims:	1. A method of monitoring and/or evaluating a ventilation regime in a mammal on a respirator, said method comprising: providing a biological sample comprising a fluid, cell, or tissue from the lung, trachea, or bronchi of said mammal; measuring the level of parathyroid hormone related protein (PTHrP) where a lower level of PTHrP, as compared to the level found in a comparable sample from a normal healthy mammal indicates that said ventilation regime is suboptimal; and where when said level of PTHrP is reduced thereby indicating that the ventilation regime is suboptimal, adjusting said ventilation regime to reduce tidal ventilation volume and/or ventilation pressure thereby reducing alveolar overdistension and increasing PTHrP production which reduces lipofibroblast to myofibroblast transdifferentiation in said mammal. 2. The method of claim 1, where said mammal is a mammal diagnosed with a lung disease. 3. The method of claim 2, wherein said lung disease is a disease selected from the group consisting of bronchoplumonary dysplasia, asthma, emphysema, and idiopathic pulmonary fibrosis. 4. The method of claim 1, wherein said biological sample is a tracheal aspirate. 5. The method of claim 1, wherein said mammal is a non-human. 6. The method of claim 1, wherein said mammal is a human. 7. The method of claim 1, wherein said mammal is a human child or infant. 8. The method of claim 1, wherein said measuring is via a method selected from the group consisting of capillary electrophoresis, a Western blot, mass spectroscopy, ELISA, immunochromatography, and immunohistochemistry. 9. The method of claim 1, wherein said mammal is a mammal diagnosed with a chronic pulmonary insufficiency. 10. The method of claim 1, wherein said method further comprises administering a PPAR gamma ligand to said mammal to reduce said lipofibroblast to myofibroblast transdifferentiation.

Details for Patent 8,293,479

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2022-05-02